Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 27 | 2025 | 338 | 7.220 |
Why?
|
| Medicare Part C | 12 | 2025 | 35 | 5.320 |
Why?
|
| Motivational Interviewing | 8 | 2025 | 51 | 4.580 |
Why?
|
| Drug Monitoring | 11 | 2026 | 292 | 4.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 744 | 4.120 |
Why?
|
| Hypoglycemic Agents | 7 | 2026 | 480 | 3.630 |
Why?
|
| Hypertension | 13 | 2025 | 1356 | 3.560 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 185 | 3.070 |
Why?
|
| Diabetes Mellitus | 10 | 2025 | 889 | 2.580 |
Why?
|
| Atrial Fibrillation | 6 | 2025 | 738 | 2.520 |
Why?
|
| Smoking Cessation | 7 | 2016 | 191 | 2.500 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 414 | 2.440 |
Why?
|
| Anticoagulants | 5 | 2025 | 605 | 2.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2026 | 1459 | 2.130 |
Why?
|
| Medicare | 16 | 2026 | 442 | 1.820 |
Why?
|
| Aged | 52 | 2026 | 21025 | 1.810 |
Why?
|
| Smoking | 8 | 2016 | 932 | 1.760 |
Why?
|
| United States | 43 | 2026 | 12072 | 1.720 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2025 | 133 | 1.710 |
Why?
|
| Retrospective Studies | 52 | 2026 | 17753 | 1.660 |
Why?
|
| Drug Therapy, Combination | 10 | 2026 | 1173 | 1.420 |
Why?
|
| Medicare Part D | 2 | 2021 | 12 | 1.310 |
Why?
|
| Antipsychotic Agents | 8 | 2025 | 375 | 1.300 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 2121 | 1.230 |
Why?
|
| Administration, Oral | 9 | 2025 | 711 | 1.140 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 34 | 1.130 |
Why?
|
| Breast Neoplasms | 13 | 2025 | 2602 | 1.120 |
Why?
|
| Rivaroxaban | 2 | 2024 | 49 | 1.030 |
Why?
|
| Stroke | 3 | 2025 | 1061 | 1.010 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 60 | 1.010 |
Why?
|
| Humans | 90 | 2026 | 131163 | 0.990 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 6797 | 0.980 |
Why?
|
| Markov Chains | 2 | 2024 | 101 | 0.980 |
Why?
|
| Pyridones | 2 | 2024 | 140 | 0.970 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 129 | 0.970 |
Why?
|
| Weight Gain | 5 | 2025 | 393 | 0.960 |
Why?
|
| Female | 66 | 2026 | 70963 | 0.950 |
Why?
|
| Varenicline | 2 | 2016 | 12 | 0.940 |
Why?
|
| Multiple Myeloma | 2 | 2025 | 177 | 0.940 |
Why?
|
| Bupropion | 2 | 2016 | 27 | 0.930 |
Why?
|
| Male | 54 | 2026 | 64957 | 0.890 |
Why?
|
| Middle Aged | 36 | 2026 | 28601 | 0.890 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 214 | 0.870 |
Why?
|
| Pyrazoles | 2 | 2024 | 349 | 0.860 |
Why?
|
| Time-to-Treatment | 1 | 2026 | 209 | 0.830 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 98 | 0.830 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 555 | 0.830 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 17 | 0.820 |
Why?
|
| Hemorrhage | 2 | 2025 | 487 | 0.810 |
Why?
|
| Obesity | 6 | 2023 | 2426 | 0.760 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 789 | 0.760 |
Why?
|
| Medicaid | 5 | 2026 | 268 | 0.730 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1272 | 0.730 |
Why?
|
| Texas | 15 | 2025 | 3686 | 0.730 |
Why?
|
| Warfarin | 2 | 2022 | 121 | 0.710 |
Why?
|
| Students | 3 | 2013 | 250 | 0.700 |
Why?
|
| Logistic Models | 11 | 2021 | 1797 | 0.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1336 | 0.670 |
Why?
|
| Insulin | 1 | 2026 | 1149 | 0.670 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2025 | 251 | 0.670 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 821 | 0.620 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2024 | 88 | 0.610 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 76 | 0.600 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 83 | 0.590 |
Why?
|
| Benchmarking | 1 | 2020 | 137 | 0.590 |
Why?
|
| Adult | 34 | 2026 | 31282 | 0.580 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 165 | 0.570 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 91 | 0.560 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 237 | 0.550 |
Why?
|
| Social Class | 4 | 2025 | 214 | 0.540 |
Why?
|
| Cancer Survivors | 2 | 2018 | 283 | 0.530 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 327 | 0.510 |
Why?
|
| Buprenorphine | 3 | 2025 | 128 | 0.500 |
Why?
|
| Hospitalization | 3 | 2020 | 1950 | 0.500 |
Why?
|
| Health Care Costs | 1 | 2020 | 407 | 0.490 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3829 | 0.480 |
Why?
|
| Drug Combinations | 4 | 2020 | 270 | 0.470 |
Why?
|
| Patient Readmission | 1 | 2020 | 442 | 0.470 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 81 | 0.470 |
Why?
|
| Arabs | 1 | 2015 | 29 | 0.470 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 33 | 0.460 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 37 | 0.460 |
Why?
|
| Universities | 3 | 2013 | 125 | 0.450 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 87 | 0.450 |
Why?
|
| Tobacco Products | 1 | 2015 | 60 | 0.450 |
Why?
|
| Telephone | 4 | 2025 | 111 | 0.440 |
Why?
|
| Primary Health Care | 1 | 2021 | 775 | 0.430 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 150 | 0.430 |
Why?
|
| Blood Glucose | 5 | 2025 | 1117 | 0.430 |
Why?
|
| Proportional Hazards Models | 4 | 2026 | 1410 | 0.420 |
Why?
|
| Young Adult | 14 | 2025 | 10103 | 0.420 |
Why?
|
| Opioid-Related Disorders | 3 | 2025 | 354 | 0.410 |
Why?
|
| Schizophrenia | 1 | 2016 | 324 | 0.390 |
Why?
|
| Health Behavior | 1 | 2015 | 387 | 0.380 |
Why?
|
| Pharmacists | 3 | 2020 | 104 | 0.370 |
Why?
|
| Social Perception | 1 | 2013 | 52 | 0.370 |
Why?
|
| Metformin | 2 | 2026 | 174 | 0.360 |
Why?
|
| Risk-Taking | 2 | 2012 | 96 | 0.360 |
Why?
|
| Nicotine | 1 | 2013 | 115 | 0.350 |
Why?
|
| Databases, Factual | 3 | 2026 | 1240 | 0.350 |
Why?
|
| Follow-Up Studies | 4 | 2026 | 5196 | 0.350 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 8 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 633 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2025 | 66 | 0.310 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 523 | 0.310 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 66 | 0.290 |
Why?
|
| Adolescent | 17 | 2025 | 20987 | 0.290 |
Why?
|
| Physicians | 4 | 2019 | 635 | 0.290 |
Why?
|
| Body Mass Index | 7 | 2025 | 1717 | 0.280 |
Why?
|
| Patient Compliance | 2 | 2015 | 463 | 0.280 |
Why?
|
| Disease Management | 1 | 2012 | 558 | 0.280 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 512 | 0.270 |
Why?
|
| Hydrocodone | 2 | 2019 | 36 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2025 | 50 | 0.260 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 28 | 0.260 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 878 | 0.240 |
Why?
|
| Polypharmacy | 1 | 2005 | 36 | 0.230 |
Why?
|
| Health Expenditures | 2 | 2024 | 136 | 0.230 |
Why?
|
| Proteasome Inhibitors | 1 | 2025 | 52 | 0.220 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 17 | 0.220 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 546 | 0.210 |
Why?
|
| Risk Factors | 8 | 2024 | 11074 | 0.210 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 712 | 0.210 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 81 | 0.210 |
Why?
|
| Dabigatran | 1 | 2024 | 26 | 0.210 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 112 | 0.210 |
Why?
|
| Thalidomide | 1 | 2024 | 36 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 1 | 2025 | 133 | 0.200 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1490 | 0.200 |
Why?
|
| Delirium | 1 | 2024 | 66 | 0.200 |
Why?
|
| Confidence Intervals | 3 | 2013 | 272 | 0.200 |
Why?
|
| Ambulatory Care | 2 | 2020 | 401 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 132 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 10 | 0.190 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 202 | 0.180 |
Why?
|
| Antidepressive Agents | 1 | 2025 | 321 | 0.180 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 50 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1071 | 0.170 |
Why?
|
| Machine Learning | 1 | 2025 | 387 | 0.170 |
Why?
|
| Cognition Disorders | 1 | 2005 | 556 | 0.170 |
Why?
|
| Pharmacies | 1 | 2021 | 15 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2024 | 282 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 18 | 0.170 |
Why?
|
| Health Surveys | 2 | 2012 | 261 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 117 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 4066 | 0.160 |
Why?
|
| Odds Ratio | 3 | 2013 | 1211 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2020 | 348 | 0.160 |
Why?
|
| Comorbidity | 2 | 2016 | 1595 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2022 | 197 | 0.160 |
Why?
|
| Controlled Substances | 2 | 2019 | 11 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 18 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 730 | 0.160 |
Why?
|
| HIV Infections | 3 | 2023 | 2049 | 0.160 |
Why?
|
| Neomycin | 1 | 2020 | 36 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2025 | 6459 | 0.160 |
Why?
|
| Lactulose | 1 | 2020 | 27 | 0.160 |
Why?
|
| Sex Factors | 2 | 2019 | 1356 | 0.150 |
Why?
|
| Sexual Behavior | 2 | 2013 | 232 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 67 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 919 | 0.150 |
Why?
|
| Acute Pain | 1 | 2019 | 20 | 0.150 |
Why?
|
| Forecasting | 1 | 2021 | 351 | 0.150 |
Why?
|
| Psychological Theory | 2 | 2016 | 34 | 0.150 |
Why?
|
| Military Personnel | 2 | 2013 | 219 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12936 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 496 | 0.140 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 604 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 369 | 0.140 |
Why?
|
| Intention | 2 | 2016 | 105 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 222 | 0.140 |
Why?
|
| Health Services | 1 | 2018 | 69 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1378 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 248 | 0.130 |
Why?
|
| Quinolines | 1 | 2019 | 118 | 0.130 |
Why?
|
| Standard of Care | 1 | 2018 | 133 | 0.130 |
Why?
|
| Health Care Surveys | 2 | 2019 | 276 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 164 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2019 | 447 | 0.130 |
Why?
|
| Age Factors | 2 | 2019 | 2825 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 690 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 293 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1246 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 182 | 0.130 |
Why?
|
| Perception | 2 | 2022 | 231 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2019 | 168 | 0.120 |
Why?
|
| Middle East | 2 | 2016 | 36 | 0.120 |
Why?
|
| Smoking Prevention | 1 | 2016 | 34 | 0.120 |
Why?
|
| Child | 10 | 2025 | 26341 | 0.120 |
Why?
|
| Time Factors | 1 | 2026 | 6196 | 0.120 |
Why?
|
| Recurrence | 1 | 2020 | 1489 | 0.120 |
Why?
|
| Depression | 1 | 2025 | 1320 | 0.120 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 22 | 0.120 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 33 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1445 | 0.110 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 67 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2023 | 910 | 0.110 |
Why?
|
| Linear Models | 1 | 2017 | 688 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 441 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2018 | 5063 | 0.110 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 46 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 726 | 0.100 |
Why?
|
| Socioeconomic Factors | 3 | 2025 | 915 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1345 | 0.100 |
Why?
|
| Propylene Glycol | 1 | 2013 | 8 | 0.100 |
Why?
|
| Social Values | 1 | 2013 | 46 | 0.090 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 61 | 0.090 |
Why?
|
| Pakistan | 1 | 2012 | 99 | 0.090 |
Why?
|
| Jordan | 1 | 2012 | 9 | 0.090 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 95 | 0.090 |
Why?
|
| India | 1 | 2012 | 234 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 28 | 0.090 |
Why?
|
| Focus Groups | 1 | 2013 | 239 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 650 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 421 | 0.080 |
Why?
|
| Overweight | 1 | 2014 | 387 | 0.080 |
Why?
|
| Data Collection | 1 | 2013 | 370 | 0.080 |
Why?
|
| Health Personnel | 1 | 2016 | 541 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 123 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 554 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 82 | 0.080 |
Why?
|
| Cholesterol | 2 | 2023 | 539 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2025 | 824 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 194 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 269 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 677 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 732 | 0.070 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 18 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2596 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 387 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 3360 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3359 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2025 | 844 | 0.060 |
Why?
|
| New England | 1 | 2004 | 10 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2025 | 66 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2005 | 164 | 0.050 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.050 |
Why?
|
| Purines | 1 | 2025 | 118 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 732 | 0.050 |
Why?
|
| Aripiprazole | 1 | 2024 | 22 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 761 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2025 | 161 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 80 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 66 | 0.050 |
Why?
|
| Pyridines | 1 | 2025 | 255 | 0.050 |
Why?
|
| Piperazines | 1 | 2025 | 265 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 295 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 190 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 264 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 54 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 378 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 466 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 464 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 39 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 97 | 0.040 |
Why?
|
| Nigeria | 2 | 2013 | 71 | 0.040 |
Why?
|
| Mexico | 1 | 2022 | 190 | 0.040 |
Why?
|
| Postmenopause | 1 | 2022 | 137 | 0.040 |
Why?
|
| Sexual Partners | 2 | 2013 | 80 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 260 | 0.040 |
Why?
|
| Research | 1 | 2023 | 264 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 624 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 3016 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 707 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 75 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 157 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 569 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 215 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 120 | 0.030 |
Why?
|
| Cognition | 1 | 2023 | 829 | 0.030 |
Why?
|
| Survival Rate | 1 | 2023 | 2114 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1118 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 138 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 48 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 130 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 122 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 214 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 39 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 274 | 0.020 |
Why?
|
| Methotrexate | 1 | 2015 | 350 | 0.020 |
Why?
|
| Communication | 1 | 2016 | 543 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 95 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 49 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1634 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 211 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 15110 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 2701 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 2332 | 0.010 |
Why?
|